Previous 10 | Next 10 |
2023-05-22 10:03:29 ET Gainers: Microbot Medical ( MBOT ) +46% . Hepion Pharmaceuticals ( HEPA ) +41% . Atea Pharmaceuticals ( AVIR ) +38% . VectivBio Holding ( VECT ) +37% . CNS Pharmaceuticals ( CNSP ) +23% . Losers: Rain Oncology ( ...
– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care – – The median PFS was 3.6 months for milademetan versus 2.2 months for trabectedin with a hazard ratio of 0.89 – – Rain to host a co...
2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
2023-05-13 03:42:09 ET Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Conference Call May 11, 2023, 5:00 pm ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Robert Doebele - CSO Richard Bryce - CMO Nelson Cabatuan - SVP, Financ...
2023-05-11 16:35:44 ET Rain Oncology press release ( NASDAQ: RAIN ): Q1 GAAP EPS of -$0.56 beats by $0.05 . As of March 31, 2023, Rain had $109.8 million in cash, cash equivalents and short-term investments. Consistent with the prior quarter, Rain ( RAIN ) will...
– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial – – Required...
NEWARK, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that ...
NEWARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates ...
NEWARK, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates ...
2023-03-10 11:41:50 ET Gainers: Euda Health ( EUDA ) +53% . Unicycive ( UNCY ) +27% . Tenon Medical ( TNON ) +12% . Rain ( RAIN ) +11% . Altamira ( CYTO ) +11% . Losers: Meihua International ( MHUA ) -34% . Fr...
News, Short Squeeze, Breakout and More Instantly...
Rain Therapeutics Inc. Company Name:
RAIN Stock Symbol:
NASDAQ Market:
Rain Therapeutics Inc. Website:
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to acquire ...
NEW YORK, NY / ACCESSWIRE / January 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Eagle Bulk Shipping Inc. (NYSE:EGLE...